MSB 2.29% $1.07 mesoblast limited

Hey guys I just wanted to create a thread discussing some of the...

  1. 208 Posts.
    lightbulb Created with Sketch. 133
    Hey guys I just wanted to create a thread discussing some of the differences between Ryoncil and Jakafi trial results prior to approval/rejection from the fda. From what I understand Novartis did a single arm trial with only a small number of patients prior to approval due to it demonstrating approx 69% overall response rate vs around 30% in the standard care group however there were significant adverse events such as thrombocytopenia, anaemia and cytomegalovirus etc. I get that Jakafi was already approved for other conditions and has a defined MOA but how can you turn down Ryoncil and not Jakafi with their relative safety profiles. Why can’t mesoblast perform a retrospective study on their patients in Japan and use that to support efficacy etc
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.07
Change
-0.025(2.29%)
Mkt cap ! $1.216B
Open High Low Value Volume
$1.10 $1.10 $1.06 $4.942M 4.613M

Buyers (Bids)

No. Vol. Price($)
6 70659 $1.07
 

Sellers (Offers)

Price($) Vol. No.
$1.07 43531 2
View Market Depth
Last trade - 16.10pm 20/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.